# Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients

> **NCT06931119** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Rabin Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Pruritus

## Interventions

- **DRUG:** EMEND® (EE mend) (aprepitant) capsules (80mg +125mg) Marketing Authorization Holder and Importer: Merck Sharp & Dohme (Israel-1996) Company Ltd.

## Key facts

- **NCT ID:** NCT06931119
- **Lead sponsor:** Rabin Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-30
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06931119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06931119, "Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06931119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*